{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:23:47Z","timestamp":1780377827841,"version":"3.54.1"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T00:00:00Z","timestamp":1535932800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00108-018-0486-2","type":"journal-article","created":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T07:36:12Z","timestamp":1535960172000},"page":"1224-1228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Kardiovaskul\u00e4res Risiko bei Patienten mit Gicht","Cardiovascular risk in gout patients"],"prefix":"10.1007","volume":"59","author":[{"given":"D.","family":"M\u00fcller-Wieland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Nitschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,3]]},"reference":[{"key":"486_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12872-018-0757-9","volume":"18","author":"M Bredemeier","year":"2018","unstructured":"Bredemeier M, Lopes LM, Eisenreich MA et al (2018) Xanthine oxidase inhibitors for prevention of cardiovascular events: a\u00a0systematic review and meta-analysis of randomized controlled trials. Bmc Cardiovasc Disord 18:24. \n                    https:\/\/doi.org\/10.1186\/s12872-018-0757-9","journal-title":"Bmc Cardiovasc Disord"},{"key":"486_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2015.11.026","volume":"29","author":"M Kanbay","year":"2016","unstructured":"Kanbay M, Jensen T, Solak Y et\u00a0al (2016) Uric acid in metabolic syndrome: from an innocent bystander to a\u00a0central player. Eur J Intern Med 29:3\u20138","journal-title":"Eur J Intern Med"},{"key":"486_CR3","doi-asserted-by":"publisher","first-page":"F993","DOI":"10.1152\/ajprenal.00637.2014","volume":"308","author":"SM Kim","year":"2015","unstructured":"Kim SM, Lee SH, Kim YG et al (2015) Hyperuricemia-induced NLRP3 ativation of macrophages contributes to the progression of diabetic nephropathy. Am J Physiol Renal Physiol 308:F993\u2013F1003","journal-title":"Am J Physiol Renal Physiol"},{"key":"486_CR4","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridgker","year":"2017","unstructured":"Ridgker PM, Everett BM, Thuren T et\u00a0al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N\u00a0Engl J Med 377:1119\u20131131","journal-title":"N Engl J Med"},{"key":"486_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.numecd.2011.02.008","volume":"23","author":"G Silbernagel","year":"2013","unstructured":"Silbernagel G, Hoffmann MM, Grammer TB et\u00a0al (2013) Uric acid is predictive of cardiovascular mortality and sudden cardiac death in subjects referred for coronary angiography. Nutr Metab Cardiovasc Dis 23:46\u201352","journal-title":"Nutr Metab Cardiovasc Dis"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-018-0486-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0486-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0486-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T23:04:19Z","timestamp":1567465459000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-018-0486-2"}},"subtitle":["Cardiovascular Safety of Febuxostat or Allopurinol in Participants with Gout and Cardiovascular Comorbidities (CARES)"],"short-title":[],"issued":{"date-parts":[[2018,9,3]]},"references-count":5,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["486"],"URL":"https:\/\/doi.org\/10.1007\/s00108-018-0486-2","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,3]]},"assertion":[{"value":"3 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"D.\u00a0M\u00fcller-Wieland und S.\u00a0Nitschmann geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}